| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_670101b0e1b717a61558c95d26de20eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-15 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-16 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 |
| filingDate |
1983-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8de41ed7e2068d4b077aeaedf5c2333b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_905e4bd8b79da865dfd8935b141dd83c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_712cfda5835875e046a03434ac0efc92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbca37b1c9a2cc68962829c39b96a6d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8784a2e441319ff420bbfec6420ae25c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_583defceecc7663da8740f352e32c798
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_447679b90f69efb3bc8454878dd09a54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_702cd7b5f6d152ff6d9367a0800b33b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84f8d3195743bdc012acfa94d15e4879 |
| publicationDate |
1983-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
SE-8302075-D0 |
| titleOfInvention |
Vasopressin analogues |
| abstract |
Vasopressin analogs of the formula <IMAGE> wherein R1 is H, R2 is CH2S and R3 is D-Arg, R1 is NH2, R2 is S-S and R3 is D-Arg or L-Orn are described. The described analogs resist enzymatic cleavage while retaining their effect on the central nervous system. These compounds lack a glycinamide residue in the 9 position and have the L-arginine in the 8 position replaced with its stereoisomeric form or with an ornithine residue. The compounds evidence little or no peripheral endocrine effects of natural vasopressin. |
| priorityDate |
1982-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |